- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05224778
DMCRN-02-001: Evaluación de criterios de valoración pediátricos en DM1 (ASPIRE-DM1)
Evaluación de criterios de valoración pediátricos en DM1 (ASPIRE-DM1)
The overall goal of the study is to establish valid clinical endpoint assessments for children with congenital myotonic dystrophy type 1 and develop biomarkers for the condition.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Myotonic dystrophy type-1 (DM1) is an autosomal dominant disorder caused by a toxic CTG repeat expansion in the 3'UTR of the DMPK gene. DM1 is the most common adult-onset muscular dystrophy, with an overall prevalence of 1:8000. In approximately 10-20% of individuals with DM1, the onset of symptoms occurs at birth, which is known as congenital myotonic dystrophy (CDM).
Previous studies have enrolled a very limited number of children with CDM.
The rationale for this study is to include a larger population of patients with CDM in order to determine developmental milestones, measures of physical and cognitive function and quality of life, and correlate functional outcome measures with potential biomarkers in CDM .
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Ruby Langeslay
- Número de teléfono: 804-828-8481
- Correo electrónico: ruby.langeslay@vcuhealth.org
Copia de seguridad de contactos de estudio
- Nombre: Jennifer Raymond
- Número de teléfono: 804-828-6318
- Correo electrónico: jennifer.raymond@vcuhealth.org
Ubicaciones de estudio
-
-
California
-
Los Angeles, California, Estados Unidos, 90095
- Reclutamiento
- University of California, Los Angeles
-
Contacto:
- Merve Kaleli
- Correo electrónico: MKaleli@mednet.ucla.edu
-
Investigador principal:
- Perry Shieh, MD, PhD
-
Contacto:
- Dennis Fernando
- Número de teléfono: 310-825-3264
- Correo electrónico: DeFernando@mednet.ucla.edu
-
-
Kansas
-
Fairway, Kansas, Estados Unidos, 66205
- Reclutamiento
- University of Kansas Medical Center
-
Investigador principal:
- Jeffrey Statland, MD
-
Contacto:
- Michaela Walker
- Correo electrónico: mwalker20@kumc.edu
-
Contacto:
- Cassidy Nelson
- Correo electrónico: cnelson15@kumc.edu
-
-
New York
-
Rochester, New York, Estados Unidos, 14642
- Reclutamiento
- University of Rochester Medical Center
-
Contacto:
- Jim Hilbert
- Correo electrónico: james_hilbert@urmc.rochester.edu
-
Contacto:
- Jeanne Dekdebrun
- Correo electrónico: jeanne_dekdebrun@urmc.rochester.edu
-
Investigador principal:
- Bohoon Lee, MD
-
-
Virginia
-
Richmond, Virginia, Estados Unidos, 23298
- Reclutamiento
- Virginia Commonwealth University
-
Contacto:
- Shantel Kyles
- Correo electrónico: shantel.brown@vcuhealth.org
-
Investigador principal:
- Nicholas E. Johnson, MD
-
Contacto:
- Jodie Howell
- Correo electrónico: jodie.howell@vcuhealth.org
-
-
-
-
-
Milan, Italia, 20162
- Reclutamiento
- Centro Clinico NeMO
-
Contacto:
- Michela Nani
- Correo electrónico: michela.nani@centrocliniconemo.it
-
Contacto:
- Luca Mauro
- Correo electrónico: luca.mauro@centrocliniconemo.it
-
Investigador principal:
- Valeria Sansone, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
30 children with CDM
Descripción
Inclusion Criteria:
- Age neonate to 3 years 11 months at enrollment.
- A diagnosis of CDM, which is defined as children having symptoms of myotonic dystrophy in the newborn period (<30 days), such as hypotonia, feeding or respiratory difficulty, requiring hospitalization to a ward or to the neonatal intensive care unit for more than 72 hours; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4>1,500).
- Guardian is willing and able to sign consent and follow study procedures
Exclusion Criteria:
- Any other non-DM1 illness that would interfere with the ability or results of the study in the opinion of the site investigator
- Significant trauma within one month
- Internal metal or devices (exclusion for DEXA component)
- History of bleeding disorder or platelet count <50,000
- History of reaction to local anesthetic
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
Congenital Myotonic Dystrophy (CDM)
CDM group includes those aged neonate to 3 years, 11 months at enrollment. Individuals must have a diagnosis of CDM, which is defined as children having symptoms of myotonic dystrophy in the newborn period (<30 days), such as hypotonia, feeding or respiratory difficulty, requiring hospitalization to a ward or to the neonatal intensive care unit for more than 72 hours; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4>1,500). |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
To evaluate motor milestone attainment in individuals with CDM and ChDM and compare to typically developing children
Periodo de tiempo: Through study completion at 18 months
|
Milestone Assessment using Peabody definitions: This survey would ask parents to assess the age of motor milestones in days, months of infant age. Birth history, including prematurity, ventilatory status, and feeding problems would also be collected on the CRF. Feeding and ventilatory support, as well as height and weight will be collected at each study visit. |
Through study completion at 18 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Dysarthria Assessment
Periodo de tiempo: Through study completion at 18 months
|
A blinded, standardized video assessment tabulating language milestones by a trained rater will be conducted at each visit. |
Through study completion at 18 months
|
|
Vineland
Periodo de tiempo: Through study completion at 18 months
|
The Vineland will be administered by an interviewer to ensure standardized intake of data. This assessment will capture the adaptive function, including gross motor and fine motor, as reported by the parent proxy. |
Through study completion at 18 months
|
|
CCMDHI
Periodo de tiempo: Through study completion at 18 months
|
The congenital and childhood myotonic dystrophy health index is a disease specific patient or proxy reported outcome measure specific to these conditions. The current study will utilize the proxy version. |
Through study completion at 18 months
|
|
Domain Delta
Periodo de tiempo: Through study completion at 18 months
|
This assessment asks parents for global impression of change related to the baseline visit and will be used as an anchoring measure for the statistical analyses. |
Through study completion at 18 months
|
|
Gross Motor Function Measure (GMFM-88)
Periodo de tiempo: Through study completion 18 months
|
The GMFM assesses functional abilities like lying/rolling, sitting, crawling/kneeling, standing, and walking, running, and jumping. |
Through study completion 18 months
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Correlate the functional outcome measures with potential biomarkers in CDM.
Periodo de tiempo: Baseline
|
Fine needle muscle biopsy:On the baseline visit, a fine needle aspirate will be performed. Biopsy will only be peformed once to minimize the risk. The procedure will be performed with local anesthesia (1% lidocaine without epinephrine and free of preservatives) of the vastus lateralis. Following lidocaine injection, a fine needle will be used to aspirate the quadriceps muscle to obtain a total of one aspirate. The aspirate will be flash frozen in liquid nitrogen. A similar procedure has been performed on adults with DM1, and the average biopsy yields sufficient tissue for RNA-Seq analysis. |
Baseline
|
|
Blood Sampling
Periodo de tiempo: Baseline, month 12, month 18
|
DNA and RNA samples will be processed by Virginia Commonwealth University. |
Baseline, month 12, month 18
|
|
Muscle mass, DEXA
Periodo de tiempo: Baseline, month 12, month 18
|
Lean muscle mass will be evaluated using serial DEXA scans as an exploratory endpoint. All sites will use a Hologic DEXA scanner. Investigators will evaluate whole body lean mass, left and right arm lean mass, and left and right leg lean mass. Particularly early in childhood, investigators would expect rapid changes in lean muscle mass. If there were a divergence between controls and subjects with CDM, this would provide evidence that CDM is a disorder of muscle maturity, as well as provide a potential biomarker. |
Baseline, month 12, month 18
|
|
World Health Organization (WHO) Motor Milestones
Periodo de tiempo: Through study completion at 18 months
|
The WHO Motor Milestones is a set of 6 standardized motor milestones that include 1) Sitting without support, 2) Standing with assistance, 3) Hands-&-knees crawling, 4) Walking with assistance, 5) Standing alone, and 6) Walking alone. |
Through study completion at 18 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Nicholas E. Johnson, MD, Virginia Commonwealth University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades musculoesqueléticas
- Enfermedades del Sistema Nervioso
- Enfermedades Musculares
- Enfermedades Neuromusculares
- Enfermedades Genéticas Congénitas
- Enfermedades neurodegenerativas
- Trastornos Heredodegenerativos, Sistema Nervioso
- Trastornos Musculares Atróficos
- Distrofias Musculares
- Trastornos miotónicos
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Distrofia miotónica
Otros números de identificación del estudio
- HM20023386
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .